DetoxiGenomic® Saliva Profile
This test evaluates single nucleotide polymorphisms (SNPs) associated with increased risk of impaired detoxification capacity especially when exposed to environmental toxins. It also identifies individuals potentially susceptible to adverse drug reactions.
Phase I: Cytochrome P-450
• CYP1A1 • CYP2A6 • CYP2C9 • CYP3A4 • CYP1B1 • CYP2D6 • CYP1C19
Phase I is the first line of defense in the detoxification of all environmental toxins, including pesticides, herbicides, pollutants, and solvents, pharmaceuticals and nutraceuticals, as well as many of the body’s own waste products (including steroid hormones).
Phase II: Conjugation of Toxins and Elimination
Polymorphisms may lead to impaired metabolism of the catecholamine neurotransmitters (dopamine, epinephrine, and norepinephrine) and may predispose individuals to anxiety , ADHD, alcoholism, and rapid cycling in bipolar individuals.
Acetylation (N-acetyl transferase)
• NAT1 • NAT2
NAT detoxifies many environmental toxins, including tobacco smoke and exhaust fumes. Polymorphisms may result in slow or rapid acetylation, both associated with increased risk of lung, colon, bladder , or head & neck cancer.
Glutathione Conjugation (glutathione s-transferase)
• GSTM1 • GSTT1 • GSTP1
GST detoxifies many water-soluble environmental toxins, including solvents, herbicides, fungicides, and heavy metals (eg, mercury , cadmium, and lead). Defects in GST activity can contribute to fatigue syndromes and many cancers.
Oxidative Protection (superoxide dismutase)
• SOD1 • SOD2
Mutations affecting these antioxidant enzymes can lead to increased free radical activity and cell damage, and may increase the risk of developing neurodegenerative disorders.